Thelansis

Gallbladder Cancer (GC) Market Outlook Thelansis’s “Gallbladder Cancer (GC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gallbladder Cancer (GC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajec...

Gallbladder Cancer (GC) Market Outlook Thelansis’s “Gallbladder Cancer (GC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gallbladder Cancer (GC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Gallbladder Cancer (GC) Overview Gallbladder cancer (GC) is a rare malignancy but represents almost half of all biliary tract cancer. The chronic inflammation of the bile duct tissue accumulates successive genomic mutations that lead to malignant transformation. The most common mutations described are oncogenes K-RAS and tumor suppressors beta-catenin (CTNNB1). The majority of histopathology changes in gallbladder cancer appear as ade...

 Gallbladder cancer (GC) is a rare malignancy but represents almost half of all biliary tract cancer. The chronic inflammation of the bile duct tissue accumulates successive genomic mutations that lead to malignant transformation. The most common mutations described are oncogenes K-RAS and tumor suppressors beta-catenin (CTNNB1). The majority of histopathology changes in gallbladder cancer appear as adenocarcinomas (90%). Gallbladder cancer patients are frequently asymptomatic at presentation or describe vague symptoms such as abdominal pain, anorexia, indigestion, weakness, nausea or vomiting, loss of appetite, and weight loss, and can present with jaundice, which can easily be misdiagnosed as cholecystitis. Biliary obstruction by cancer causes jaundice, clay-coloured stools, cola-colored urine, and skin pruritus. ·        The incidence of Gallbladder cancer (GC) ranges from 3 to 4 per 100,000 in the USA. Thelansis’s “Gallbladder Cancer (GC) Marke...